<DOC>
	<DOCNO>NCT02442778</DOCNO>
	<brief_summary>Patients agitation secondary dementia Alzheimer 's type . The diagnosis probable Alzheimer 's disease ( AD ) base '2011 Diagnostic Guidelines Alzheimer 's Disease ' issued National Institute Aging ( NIA ) -Alzheimer 's Association ( AA ) workgroups .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability AVP-786 ( Deuterated d6-Dextromethorphan Hydrobromide d6-DM/Quinidine Sulfate Q ) Treatment Agitation Patients With Dementia Alzheimer 's Type</brief_title>
	<detailed_description>Eligible participant study must diagnosis probable AD must clinically meaningful agitation secondary AD . This multicenter , randomize , placebo-controlled study , consist 12 week treatment . Approximately 325 participant enrol approximately 50 center North America . Study medication administer orally twice-daily Day 1 Day 85 . Screening must occur within 4 week prior randomization . Following screening procedure assessment inclusion exclusion criterion , eligible participant randomize study .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Diagnosis probable Alzheimer 's Disease ( AD ) The participant clinically significant , moderate/severe agitation time screen least 2 week prior randomization The diagnosis agitation must meet International Psychogeriatric Association ( IPA ) provisional definition agitation Either patient resident assistedliving facility skilled nursing home Clinical Global Impression Severity ( CGIS ) score assess Agitation &gt; =4 ( moderately ill ) screen baseline MiniMental State Examination ( MMSE ) score 6 26 ( inclusive ) screen baseline Caregiver able willing comply require study procedure . In order qualify reliable informant ( i.e. , caregiver ) capable assess change participant 's condition study , individual must spend minimum 2 hour per day 4 day per week participant . Participant dementia predominantly nonAlzheimer 's type ( e.g. , vascular dementia , frontotemporal dementia , Parkinson 's disease , substanceinduced dementia ) Participants coexistent clinically significant unstable systemic disease could confound interpretation safety result study ( e.g. , malignancy , poorly control diabetes , poorly control hypertension , unstable pulmonary , renal hepatic disease , unstable ischemic cardiac disease , dilate cardiomyopathy , unstable valvular heart disease ) Participant myasthenia gravis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>